

199at09.us
8602*36

19 (see Amended sheets 14, 15 and 16 attached to the filing papers). If necessary, it is requested that the amended sheets 14, 15 and 16 be substituted for pages 14, 15 and 16 of the application as filed (i.e., pages 14, 15 and 16 of the English language translation of PCT/EP00/03949) before the claim amendments shown in this Preliminary Amendment are entered.

-
4. (Amended) A vector comprising a sequence as claimed in claim 1.
5. (Amended) A host organism, except a human, comprising a vector as claimed in claim 4.
-

12. (Amended) A pharmaceutical comprising a nucleic acid as claimed in claim 1 and, where appropriate, pharmaceutically acceptable additives and/or excipients.
13. (Amended) A process for producing a pharmaceutical for the treatment of cancer, autoimmune diseases, in particular Grave's disease, spinal muscular atrophy, β '-thalassemia, cancers related to the c-erb oncogene, hepatitis C infection, herpes simplex virus infection, systemic lupus erythematosus, Hermansky-Pudlak syndrome, which comprises formulating a nucleic acid as claimed in claim 1 together with a pharmaceutically acceptable additive and/or excipient.

199at09.us
8602*36

- Q2
Ant
14. (Amended) A diagnostic agent comprising nucleic acid as claimed in claim 1 and, where appropriate, pharmaceutically acceptable additives and/or excipients.
15. (Amended) A process for producing a diagnostic agent for diagnosis of Grave's disease, spinal muscular atrophy, β' -thalassemia, cancers related to the c-erb oncogene, hepatitis C infection, herpes simplex virus infection, systemic lupus erythematosus, Hermansky-Pudlak syndrome, which comprises adding a pharmaceutically acceptable carrier to a nucleic acid as claimed in claim 1.
-

Please add new claims 16 - 23 as follows.

- Q3
- 16. (New) A vector comprising a recombinant DNA molecule as claimed in claim 2.
17. (New) A vector comprising a recombinant DNA molecule as claimed in claim 3.
18. (New) A host organism, except a human, comprising a recombinant DNA molecule as claimed in claim 2.
19. (New) A host organism, except a human, comprising a recombinant DNA molecule as claimed in claim 3.

199at09.us
8602*36

- a3
Cont
20. (New) A pharmaceutical comprising a spliceosomal protein as claimed in claim 8 and, where appropriate, pharmaceutically acceptable additives and/or excipients.
21. (New) A process for producing a pharmaceutical for the treatment of cancer, autoimmune diseases, in particular Grave's disease, spinal muscular atrophy, β' -thalassemia, cancers related to the c-erb oncogene, hepatitis C infection, herpes simplex virus infection, systemic lupus erythematosus, Hermansky-Pudlak syndrome, which comprises formulating a spliceosomal protein as claimed in claim 8 together with a pharmaceutically acceptable additive and/or excipient.
22. (New) A diagnostic agent comprising a spliceosomal protein as claimed in claim 8 and, where appropriate, pharmaceutically acceptable additives and/or excipients.
23. (New) A process for producing a diagnostic agent for diagnosis of Grave's disease, spinal muscular atrophy, β' -thalassemia, cancers related to the c-erb oncogene, hepatitis C infection, herpes simplex virus infection, systemic lupus erythematosus, Hermansky-Pudlak syndrome, which comprises adding a pharmaceutically acceptable carrier to a spliceosomal protein as claimed in claim 8. - -
-